SCHEMBL14023448

SCHEMBL14023448

Oc1ccc(-c2nc(-c3ccc(Br)cc3)c(-c3ccc(Br)cc3)[nH]2)cc1

nearest known ligand 0.88

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 8/20 0.88
MAPK13 O15264 7/20 0.88
MAPK12 P53778 7/20 0.88
MAPK11 Q15759 7/20 0.88
GCGR P47871 5/20 0.88
MAPT P10636 5/20 0.88
TP53 P04637 4/20 0.88
NOX1 Q9Y5S8 1/20 0.66
RAF1 P04049 3/20 0.64
BRAF P15056 2/20 0.64
CSNK1D P48730 2/20 0.62
CSNK1E P49674 2/20 0.62
KDM4E B2RXH2 1/20 0.62
CIT O14578 1/20 0.62
GAK O14976 1/20 0.62
RIPK2 O43353 1/20 0.62
BRD4 O60885 1/20 0.62
GMNN O75496 1/20 0.62
PRKD3 O94806 1/20 0.62
MAP4K4 O95819 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12561692 0.94 MAPK13 (1.00) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL14045551 0.93 MAPK14 (0.77) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL8010209 0.91 NOX1 (0.76) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL28158811 0.91 MAPK13 (0.86) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL14220431 0.89 MAPK14 (0.71) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL11176392 0.85 MAPK13 (1.00) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL9619859 0.85 MAPK13 (0.85) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL15401173 0.85 MAPK13 (0.85) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL252964 0.85 MAPK13 (0.85) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL5307418 0.85 MAPK13 (0.85) MAPK14MAPK13MAPK12MAPK11GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1692113-B1 ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS LORUS THERAPEUTICS INC (CA) 2017-09-27 EP disclosed
US-20150374669-A1 ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS LORUS THERAPEUTICS INC. (CA) 2015-12-31 US disclosed
US-20150374669-A1 ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS LORUS THERAPEUTICS INC. (CA) 2015-12-31 US disclosed
US-8969372-B2 Aryl imidazoles and their use as anti-cancer agents Aptose Boisciences Inc. (CA) 2015-03-03 US disclosed
US-8969372-B2 Aryl imidazoles and their use as anti-cancer agents Aptose Boisciences Inc. (CA) 2015-03-03 US disclosed
US-20080262015-A9 Aryl imidazoles and their use as anti-cancer agents LORUS THERAPEUTICS INC. (CA) 2008-10-23 US disclosed
US-20080262015-A9 Aryl imidazoles and their use as anti-cancer agents LORUS THERAPEUTICS INC. (CA) 2008-10-23 US disclosed
WO-2005047266-A9 ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS LORUS THERAPEUTICS INC (CA) 2008-04-17 WO disclosed
US-20070123553-A1 Aryl imidazoles and their use as anti-cancer agents LORUS THERAPEUTICS INC. (CA) 2007-05-31 US disclosed
US-20070123553-A1 Aryl imidazoles and their use as anti-cancer agents LORUS THERAPEUTICS INC. (CA) 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123553-A1 Aryl imidazoles and their use as anti-cancer agents AHR, AADAC, CBR3 MAPK14 3469/4885MAPK13 4059/4885MAPK12 3204/4885
US-20150374669-A1 ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS AHR, CBR3, AADAC MAPK14 3647/4885MAPK13 4087/4885MAPK12 3446/4885
US-20080262015-A9 Aryl imidazoles and their use as anti-cancer agents AHR, AADAC, CBR3 MAPK14 3469/4885MAPK13 4059/4885MAPK12 3204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.